NEXT UP

On-Demand Workshop: Responding to the COVID-19 Pandemic - Perspectives from a Clinical Laboratory  More >

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

 

Presented By :

Dr. Ed Schuuring

Prof. Dr. Ed Schuuring, Professor of Molecular Oncological Pathology, University Medical Center Groningen

Ed Schuuring studied Medical Biology at the University of Amsterdam (cum laude). In 1991 he received a staff position as a senior research scientist at the Department of Pathology at the Leiden University Medical Center. In 2001 Ed Schuuring continued his career at the Department of Pathology at the University Medical Center Groningen and was appointed as full professor in Molecular Oncological Pathology. His latest research interest is the detection and monitoring of tumor response and resistance to TKI treatment and...
More
Darryl Irwin, PhD

Darryl Irwin, PhD, Vice President, Scientific Affairs, Agena Bioscience

Darryl Irwin has been leading the Scientific Affairs and Assays by Agena operations at Agena Bioscience (and its predecessor Sequenom Inc.) in Asia Pacific, and more recently in a global capacity, for 12 years. Previously, Darryl led the genotyping division at the Australian Genome Research Facility. Darryl has also held positions at the Mater Laboratory Services, a hospital-based clinical genetics laboratory and Agen Biomedical, an immuno-diagnostics manufacturer. Darryl has a PhD from the University of Queensland in Non-Invasive Prenatal Testing (NIPT) and a BSc in Biotechnology from...
More

Stay Connected with Agena

Join The Conversation
icon_img
The U.S. FDA has granted Emergency Use Authorization for the high-throughput, low-cost MassARRAY SARS-CoV-2 Panel for in vitro diagnostic use. We enable laboratories to scale up molecular testing and respond effectively to this global crisis with a secure supply of instruments and assay reagents. Get started now!
More
icon_img
Large-scale, accurate testing is now more accessible! We are proud to announce the European launch of our SARS-CoV-2 Panel as a CE-IVD marked test. Learn how clinical laboratories can process more than 6,000 samples daily on a single MassARRAY instrument - priced at under 10 € per sample. Get started now.
More

MORE FROM OUR VIDEO LIBRARY

Webinar Recording: Going beyond EGFR – Evaluating Technologies for Molecular Genetic Testing in NSCLC
Webinar Recording: Targeted Detection of MET and NTRK Oncogenic Variants in Routine Molecular Analysis
Video: The MassARRAY System by Agena Bioscience
AMP 2019 Workshop: Low Cost, High Sensitivity: The Advantages of MALDI-TOF for Liquid Biopsy & Solid Tumor Profiling

About Agena Bioscience

A global company with a mission to help laboratories translate genomic discoveries into targeted, cost-effective testing.

Connect

The MassARRAY SARS-CoV-2 Panel is available for in vitro diagnostic use under Emergency Use Authorization by the U.S. FDA, and is CE-IVD marked in Europe. With exception of the MassARRAY SARS-CoV-2 Panel and MassARRAY Dx, all other products are For Research Use Only. Not for use in diagnostic procedures.
© 2020 Agena Bioscience